semaglutide sglt2 inhibitor vs GLP-1 for CKD: Which Is Better? Sodium-glucose cotransporter-2 inhibitors: Understanding the

Instead of consistently stepping up the dose to a target dose of 2.4 mg as the manufacturers instructions and FDAs guidance recommend, shes been sticking close to the amount she started with

A Prospective Trial of Risk Factors for Sulfonylurea-Induced Hypoglycaemia

Adverse events can be reported to the FDA through its MedWatch program to help protect public health

"On the basis of the current evidence the benefits of GLP-1 RAs outweigh the potential risks when used for the licensed indications." Mounjaro manufacturer Lilly said patient safety was the company's top priority

The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments